These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 29357804)

  • 1. ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development.
    Walles M; Connor A; Hainzl D
    Curr Top Med Chem; 2017; 17(32):3463-3475. PubMed ID: 29357804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
    Wang Y; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31288450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity.
    Wei B; Gunzner-Toste J; Yao H; Wang T; Wang J; Xu Z; Chen J; Wai J; Nonomiya J; Tsai SP; Chuh J; Kozak KR; Liu Y; Yu SF; Lau J; Li G; Phillips GD; Leipold D; Kamath A; Su D; Xu K; Eigenbrot C; Steinbacher S; Ohri R; Raab H; Staben LR; Zhao G; Flygare JA; Pillow TH; Verma V; Masterson LA; Howard PW; Safina B
    J Med Chem; 2018 Feb; 61(3):989-1000. PubMed ID: 29227683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cathepsin B Is Dispensable for Cellular Processing of Cathepsin B-Cleavable Antibody-Drug Conjugates.
    Caculitan NG; Dela Cruz Chuh J; Ma Y; Zhang D; Kozak KR; Liu Y; Pillow TH; Sadowsky J; Cheung TK; Phung Q; Haley B; Lee BC; Akita RW; Sliwkowski MX; Polson AG
    Cancer Res; 2017 Dec; 77(24):7027-7037. PubMed ID: 29046337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting HER2-positive cancer with dolastatin 15 derivatives conjugated to trastuzumab, novel antibody-drug conjugates.
    Gianolio DA; Rouleau C; Bauta WE; Lovett D; Cantrell WR; Recio A; Wolstenholme-Hogg P; Busch M; Pan P; Stefano JE; Kramer HM; Goebel J; Krumbholz RD; Roth S; Schmid SM; Teicher BA
    Cancer Chemother Pharmacol; 2012 Sep; 70(3):439-49. PubMed ID: 22821053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ADME Considerations for the Development of Biopharmaceutical Conjugates Using Cleavable Linkers.
    Tumey LN; Han S
    Curr Top Med Chem; 2017; 17(32):3444-3462. PubMed ID: 29357803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent Advances in the Linkers of Drug Conjugates.
    Deng S; Wen X; Wang J
    Curr Med Chem; 2024 Sep; ():. PubMed ID: 39289930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
    Polson AG; Calemine-Fenaux J; Chan P; Chang W; Christensen E; Clark S; de Sauvage FJ; Eaton D; Elkins K; Elliott JM; Frantz G; Fuji RN; Gray A; Harden K; Ingle GS; Kljavin NM; Koeppen H; Nelson C; Prabhu S; Raab H; Ross S; Slaga DS; Stephan JP; Scales SJ; Spencer SD; Vandlen R; Wranik B; Yu SF; Zheng B; Ebens A
    Cancer Res; 2009 Mar; 69(6):2358-64. PubMed ID: 19258515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-Cleavable Self-immolative Maytansinoid Antibody-Drug Conjugates Designed To Provide Improved Bystander Killing.
    Costoplus JA; Veale KH; Qiu Q; Ponte JF; Lanieri L; Setiady Y; Dong L; Skaletskaya A; Bartle LM; Salomon P; Wu R; Maloney EK; Kovtun YV; Ab O; Lai K; Chari RVJ; Widdison WC
    ACS Med Chem Lett; 2019 Oct; 10(10):1393-1399. PubMed ID: 31620224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of attachment site on stability of cleavable antibody drug conjugates.
    Dorywalska M; Strop P; Melton-Witt JA; Hasa-Moreno A; Farias SE; Galindo Casas M; Delaria K; Lui V; Poulsen K; Loo C; Krimm S; Bolton G; Moine L; Dushin R; Tran TT; Liu SH; Rickert M; Foletti D; Shelton DL; Pons J; Rajpal A
    Bioconjug Chem; 2015 Apr; 26(4):650-9. PubMed ID: 25643134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absorption, distribution, metabolism, and excretion considerations for the development of antibody-drug conjugates.
    Han TH; Zhao B
    Drug Metab Dispos; 2014 Nov; 42(11):1914-20. PubMed ID: 25048520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A preliminary study for the development of cleavable linkers using activatable fluorescent probes targeting leucine aminopeptidase.
    Kang J; Mun SK; Choi EJ; Kim JJ; Yee ST; Chang DJ
    Analyst; 2022 Nov; 147(23):5386-5394. PubMed ID: 36285914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Weinheim Bergstr Ger; 2022 Mar; 134(13):e202114016. PubMed ID: 38505643
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates: design and selection of linker, payload and conjugation chemistry.
    McCombs JR; Owen SC
    AAPS J; 2015 Mar; 17(2):339-51. PubMed ID: 25604608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guided molecular missiles for tumor-targeting chemotherapy--case studies using the second-generation taxoids as warheads.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):108-19. PubMed ID: 17663526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114016. PubMed ID: 34953094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of RGD peptidomimetic-paclitaxel conjugates bearing lysosomally cleavable linkers.
    Dal Corso A; Caruso M; Belvisi L; Arosio D; Piarulli U; Albanese C; Gasparri F; Marsiglio A; Sola F; Troiani S; Valsasina B; Pignataro L; Donati D; Gennari C
    Chemistry; 2015 Apr; 21(18):6921-9. PubMed ID: 25784522
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.